Page 137 - 202013

67（6）：1311-1320. [15] DRAWZ SM，PAPP-WALLACE KM，BONOMO RA.
[ 4 ] ZILBERBERG MD，SHORR AF，MICEK ST，et al. Multi- New β-lactamase inhibitors：a therapeutic renaissance in
drug resistance，inappropriate initial antibiotic therapy and an MDR world[J]. Antimicrob Agents Chemother，2013.
mortality in Gram-negative severe sepsis and septic DOI：10.1128/AAC.00826-13.
shock：a retrospective cohort study[J]. Crit Care，2014. [16] LIN SY，HUANG CH，KO WC，et al. Recent develop-
DOI：10.1186/s13054-014-0596-8. ments in antibiotic agents for the treatment of complicated
[ 5 ] NICOLAU DP. Carbapenems：a potent class of antibiotics intra-abdominal infections[J]. Expert Opin Pharmacother，
[J]. Expert Opin Pharmacother，2008，9（1）：23-37. 2016，17（3）：339-354.
[ 6 ] ZHANEL GG，WIEBE R，DILAY L，et al. Comparative [17] SARAH MD，ROBERT AB. Three decades of beta-lac-
review of the carbapenems[J]. Drugs，2007，67（7）：1027- tamase inhibitors[J]. Clin Microbiol Rev，2010，23（1）：
1052. 160-201.
[ 7 ] LOB SH，HACKEL MA，KAZMIERCAZK KM，et al. In [18] JACOBY GA，MUNOZPRICELS. The new β-lactamases
vitro activity of imipenem-relebactam against Gram-nega- [J]. N Engl J Med，2005. DOI：10.1056/NEJMra041359.
tive bacilli isolated from patients with lower respiratory [19] SHAHID M，SOBIA F，SINGH A，et al. Beta-lactams and
tract infections in the United States in 2015：results from beta-lactamase-inhibitors in current or potential-clinical
the SMART global surveillance program[J]. Diagn Micro- practice：a comprehensive update[J]. Crit Rev Microbiol，
biol Infect Dis，2017. DOI：10.1016/j.diagmicrobio.2017. 2009，35（2）：81-108.
02.018. [20] ZHANEL GG，LAWSON CD，ADAM H，et al. Ceftazi-
[ 8 ] LIVERMORE DM，WARNER M，MUSHTAQ S. Activity dime-avibactam：a novel cephalosporin/β-lactamase in hib-
of MK-7655 combined with imipenem against Enterobac- itor combination[J]. Drugs，2013，73（2）：159-177.
teriaceae and Pseudomonas aeruginosa[J]. J Antimicrob [21] GOLDSTEINE JC，CITRON DM，TYRRELL KL，et al.
Chemother，2013，68（10）：2286-2290. Comparative in vitro activities of relebactam，imipenem，
[ 9 ] WONG D，VAN DUIN D. Novel beta-lactamase inhibi- the combination of the two，and six comparator antimicro-
tors：unlocking their potential in therapy[J]. Drugs，2017， bial agents against 432 strains of anaerobic organisms，in-
77（6）：615-628. cluding imipenem-resistant strains[J]. Antimicrob Agents
[10] THAKARE R，DASGUPTA A，CHOPRA S. Imipenem/ Chemother，2017.DOI：10.1128/AAC.01992-17.
cilastatin sodium/relebactam fixed combination to treat [22] SNYDMAN DR，JACOBUS NV，MCDERMOTT LA. In
urinary infections and complicated intra-abdominal bacte- vitro evaluation of the activity of imipenem/relebactam
rial infections[J]. Drugs Today（Barc），2020，56（4）：241- （imipenem/MK-7655）against 451 recent clinical isolates
255. of bacteroides group and related species[J]. Antimicrob
[11] U.S. National Library of Medicine. Imipenem/relebactam/ Agents Chemother，2016. DOI：10.1128/AAC.01125-16.
cilastatin versus piperacillin/tazobactam for treatment of [23] KARLOWSKY JA，LOB SH，KAZMIERCZAK KM，
participants with bacterial pneumonia （MK-7655a-014） et al. In vitro activity of imipenem-relebactam against clin-
[EB/OL].[2020-05-25].https：//www.clinicaltrials.gov/ct2a/ ical isolates of Gram-negative bacilli isolated in hospital
show/results/NCT02493764. laboratories in the United States aspart of the SMART
[12] BLIZZARD TA，CHEN H，KIM S，et al. Discovery of 2016 program[J]. Antimicrob Agents Chemother，2018.
MK-7655，a β-lactamase inhibitor for combination with DOI：10.1128/AAC.00169-18.
Primaxin [J]. Bioorg Med Chem Lett，2014，24（3）： [24] LOB SH，HACKEL MA，KAZMIERCZAK KM，et al. In
®
780-785. vitro activity of imipenem-relebactam against Gram-nega-
[13] OLSEN I. New promising β-lactamase inhibitors for clini- tive bacilli isolated from patients with lower respiratory
cal use[J]. Eur J Clin Microbiol Infect Dis，2015，34（7）： tract infections in the United States in 2015 Results from
1303-1308. the SMART global surveillance program[J]. Diagn Micro-
[14] AMABEL L，MARIE A，OLAWOLE O，et al. Activity of biol Infect Dis，2017. DOI：10.1016/j.diagmicrobio.2017.
imipenem with relebactam against Gram-negative patho- 02.018.
gens from New York city[J]. Antimicrob Agents Chemoth- [25] PAPP-WALLACE KM，BARNES MD，ALSOP J，et al.
er，2015. DOI：10.1128/AAC.00830-15. Relebactam is a potent inhibitor of the KPC-2 β-lactamase

中国药房 2020年第31卷第13期 China Pharmacy 2020 Vol. 31 No. 13 ·1663 ·